HUE036069T2 - Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére - Google Patents

Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére

Info

Publication number
HUE036069T2
HUE036069T2 HUE14725812A HUE14725812A HUE036069T2 HU E036069 T2 HUE036069 T2 HU E036069T2 HU E14725812 A HUE14725812 A HU E14725812A HU E14725812 A HUE14725812 A HU E14725812A HU E036069 T2 HUE036069 T2 HU E036069T2
Authority
HU
Hungary
Prior art keywords
ribavirin
treatment
combination
directly acting
hcv patients
Prior art date
Application number
HUE14725812A
Other languages
English (en)
Hungarian (hu)
Inventor
Barry M Bernstein
Sandeep Dutta
Wei Liu
Thomas J Podsadecki
Andrew L Campbell
Rajeev M Menon
Chih-Wei Lin
Tianli Wang
Walid M Awni
Sven Mensing
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036069(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HUE036069T2 publication Critical patent/HUE036069T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE14725812A 2013-03-14 2014-03-14 Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére HUE036069T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
HUE036069T2 true HUE036069T2 (hu) 2018-06-28

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14725812A HUE036069T2 (hu) 2013-03-14 2014-03-14 Közvetlenül ható vírusellenes szerek és ribavirin kombinációja HCV-betegek kezelésére

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN109908353A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TWI678205B (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients
CN105658219A (zh) * 2013-10-25 2016-06-08 艾伯维公司 用于治疗hcv的方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP3383662B1 (en) 2016-01-08 2020-09-02 Entrust Datacard Corporation Card printing mechanism with card return path
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル(Telaprevir)投薬養生法
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
TWI523658B (zh) * 2010-09-21 2016-03-01 安塔製藥公司 巨環脯胺酸衍生之hcv絲胺酸蛋白酶抑制劑
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
EP3318258B1 (en) 2013-03-14 2020-05-13 AbbVie Inc. Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Also Published As

Publication number Publication date
JP6563894B2 (ja) 2019-08-21
CY1121474T1 (el) 2020-05-29
PL2968302T3 (pl) 2018-04-30
WO2014152635A9 (en) 2014-12-11
EP3318258B1 (en) 2020-05-13
CA2901818C (en) 2021-05-04
EP2968302A1 (en) 2016-01-20
LT2968302T (lt) 2017-12-27
EP3733180A1 (en) 2020-11-04
IL267927A (en) 2019-09-26
SG11201507361YA (en) 2015-10-29
SG10201709840UA (en) 2018-01-30
WO2014152635A1 (en) 2014-09-25
EP2968302B1 (en) 2017-09-06
TW202002979A (zh) 2020-01-16
CN109908353A (zh) 2019-06-21
DK2968302T3 (en) 2017-12-18
ZA201705080B (en) 2019-02-27
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
EA201890507A1 (ru) 2018-07-31
MX2015012536A (es) 2016-01-12
CN108187056A (zh) 2018-06-22
CN105007921B (zh) 2018-12-11
KR20180045055A (ko) 2018-05-03
JP2019167347A (ja) 2019-10-03
NO3090119T3 (enExample) 2018-03-31
HK1213191A1 (en) 2016-06-30
EA030482B1 (ru) 2018-08-31
US20140274934A1 (en) 2014-09-18
JP2019214585A (ja) 2019-12-19
AU2018202581A1 (en) 2018-05-10
AU2020201656A1 (en) 2020-03-26
HRP20171898T1 (hr) 2018-04-06
RS56735B1 (sr) 2018-03-30
BR112015020918A2 (pt) 2017-07-18
IL240445A0 (en) 2015-09-24
JP2016513703A (ja) 2016-05-16
AU2014239322A1 (en) 2015-08-27
SMT201800017T1 (it) 2018-03-08
IL240445B (en) 2019-07-31
KR101853605B1 (ko) 2018-05-03
EA201591701A1 (ru) 2016-02-29
EP3318258A1 (en) 2018-05-09
CN105007921A (zh) 2015-10-28
PL2968302T4 (pl) 2018-04-30
TW201505633A (zh) 2015-02-16
KR20150129035A (ko) 2015-11-18
CA2901818A1 (en) 2014-09-25
AU2014239322B2 (en) 2018-04-05
SI2968302T1 (en) 2018-04-30
AU2018202581B2 (en) 2019-12-05
EP3915559A1 (en) 2021-12-01
EP2968302B9 (en) 2019-02-13
ES2654109T3 (es) 2018-02-12
HK1255257A1 (en) 2019-08-09

Similar Documents

Publication Publication Date Title
IL264541B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
PL2935303T3 (pl) 4'-fluoronukleozydy, 4'-fluoronukleotydy i ich analogi do leczenia HCV
HUE040446T2 (hu) Szulfamoiltiofenamid-származékok és gyógyszerként történõ alkalmazásuk hepatitis B kezelésére
LT2984166T (lt) Kompozicijos, skirtos mpsi gydymui
IL244111A0 (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
IL240326B (en) System for glaucoma treatment
IL241110B (en) n-phenyl-carboxamide derivatives and their use as drugs for the treatment of type b jaundice
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
IL243082B (en) Surgical suit
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
IL242293B (en) Bacteriophage therapy
PT2968302T (pt) Combinação de agentes antivirais de ação direta e ribavirina para tratar pacientes com vhc
HUE046314T2 (hu) Pirazolopirimidon vagy pirrolotriazon származékok, eljárás ezek elõállítására és gyógyászati alkalmazásaik
FI20135231A7 (fi) Potilasalusta
HUE042196T2 (hu) Vegyületek elhízás kezelésére és alkalmazási eljárásaik
DK2976101T3 (da) Behandlingsfremgangsmåde
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
DK3041506T3 (da) Behandlingsfremgangsmåde
FI10329U1 (fi) Kaasujen käsittelylaitteisto
HRP20190035T1 (hr) Obrada krutina s visokim sadržajem sumpora
UA27795S (uk) Ковдра стьобана
TH1501000913A (th) อนุพันธ์ซัลโฟโมอิลชนิดวงแหวนคู่หลอมรวมและการใช้ของสิ่งนั้นเป็นยาสำหรับการบำบัดโรคไวรัสตับอักเสบชนิด b
FI10036U1 (fi) Potilasalusta
UA28339S (uk) Медичний пристрій-шприц
UA28338S (uk) Медичний пристрій-шприц